Management of T-Cell Engaging Immunotherapy Complications
This article will discuss T-cell–mediated immunotherapy complications and their suggested management. It is not intended to be comprehensive or applicable to every patient, so practitioners should exercise sound clinical judgment. Rather, this may serve as a starting point for further management discussions in the community. (Source: The Cancer Journal)
Source: The Cancer Journal - May 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors
Chimeric antigen receptor (CAR) T-cell therapy has been transformative for the treatment of B-cell malignancies, with CD19- and CD22-directed CARs being prime examples. However, immunoediting and ensuing antigen loss remain the major obstacles to curative therapy in up to 25% of patients. For example, to achieve the CD19-negative phenotype, malignant cells can pick from a broad array of mechanisms, including focal loss-of-function mutations, dysregulated trafficking to the cell surface, alternative splicing, and lineage switching. In other cases, where resistance is mediated by insufficient antigen density, trogocytosis ha...
Source: The Cancer Journal - May 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells
Multiple myeloma is still an incurable malignancy despite the many new therapies approved over the last decade and therefore represents a significant unmet medical need. To address this need, adoptive cellular therapies using chimeric antigen receptor (CAR) T-cells are being explored in clinical investigations. The number of CAR T-cell trials for multiple myeloma has increased exponentially over the past few years. Although the data are preliminary at this time, the results have garnered much enthusiasm in the field. Immune therapies targeting B-cell maturation antigen have been the most widely developed, and much of these...
Source: The Cancer Journal - May 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Refractory and relapsed acute myeloid leukemia (AML) and T-lineage leukemia have poor prognosis and limited therapeutic options. Adoptive cellular immunotherapies are emerging as an effective treatment for patients with chemotherapy refractory hematological malignancies. Indeed, the use of unselected donor lymphocyte infusions has demonstrated successes in treating patients with AML and T-lineage leukemia post–allogeneic transplantation. The development of ex vivo manipulation techniques such as genetic modification or selection and expansion of individual cellular components has permitted the clinical translation of a w...
Source: The Cancer Journal - May 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy is transforming the landscape for treatment of B-lineage acute lymphoblastic leukemia (B-ALL). Chimeric antigen receptor T-cell therapy makes use of T cells that have been modified to target a cancer-specific cell surface antigen. There is currently 1 Food and Drug Administration–approved CD19-directed CAR T-cell therapy for relapsed/refractory B-ALL with numerous other CAR T-cell products under clinical investigation. This review covers the development of CAR T cells for B-ALL, citing the remarkable efficacy of inducing remissions in a very high-risk population of patients....
Source: The Cancer Journal - May 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
T-Cell Receptor–Based Immunotherapy for Hematologic Malignancies
Adoptive immunotherapy with engineered T cells is at the forefront of cancer treatment. T cells can be engineered to express T-cell receptors (TCRs) specific for tumor-associated antigens (TAAs) derived from intracellular or cell surface proteins. T cells engineered with TCRs (TCR-T) allow for targeting diverse types of TAAs, including proteins overexpressed in malignant cells, those with lineage-restricted expression, cancer-testis antigens, and neoantigens created from abnormal, malignancy-restricted proteins. Minor histocompatibility antigens can also serve as TAAs for TCR-T to treat relapsed hematologic malignancies af...
Source: The Cancer Journal - May 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Introduction by the Guest Editor, Terry J. Fry
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - May 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium
The clear cell subtype of kidney cancer encompasses most renal cell carcinoma cases and is associated with the loss of von Hippel-Lindau gene function or expression. Subsequent loss or mutation of the other allele influences cellular stress responses involving nutrient and hypoxia sensing. Autophagy is an important regulatory process promoting the disposal of unnecessary or degraded cellular components, tightly linked to almost all cellular processes. Organelles and proteins that become damaged or that are no longer needed in the cell are sequestered and digested in autophagosomes upon fusing with lysosomes, or alternative...
Source: The Cancer Journal - May 1, 2019 Category: Cancer & Oncology Tags: Original Article Source Type: research
Erratum
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Erratum Source Type: research
Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia: Limitations and Possibilities in the Age of Precision Therapy
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Repurposed Drugs Trials for Ovarian Cancer
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Non–Cancer Drug Repurposing Candidates for Renal Cell Carcinoma
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Repurposed Drugs in Treating Glioblastoma Multiforme: Clinical Trials Update
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Repurposed Drugs Trials by Cancer Type: Lung Cancer
No abstract available (Source: The Cancer Journal)
Source: The Cancer Journal - March 1, 2019 Category: Cancer & Oncology Tags: Review Articles Source Type: research
